MIT researchers reported a new RNA vaccine formulation designed to withstand high temperatures, targeting one of the main logistical barriers that ultracold storage creates for broader deployment. The advance arrives as RNA platforms continue expanding beyond COVID-19 into indications including oncology, where storage and supply-chain constraints can limit practical adoption.